Matias Cordoba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matias Cordoba has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Lucchesi
Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
1 shared publication - Belén Rodríguez
Instituto de Efectividad Clínica y Sanitaria (IECS), Argentina
1 shared publication Caroline Kruse
Platelet Disorder Support Association Cleveland Ohio USA
1 shared publication- Divya Pushkarna
Evidinno Outcomes Research Inc., Vancouver, BC, Canada
1 shared publication - Drew Provan
Department of Haematology, Barts and the London School of Medicine, London, United Kingdom
1 shared publication - Erin Reineke
Sanofi, Scientific Communications Cambridge Massachusetts USA
1 shared publication
Latest Publications
- Open Access
- 20 November 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (1)
Inflammatory cytokines, inflammasomes, and neutrophil extracellular traps in primary immune thrombocytopenia pathogenesis
- 20 November 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (1)
Open AccessInflammatory cytokines, inflammasomes, and neutrophil extracellular traps in primary immune thrombocytopenia pathogenesis
- Open Access
- 17 August 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (3) , 1038-1046
Patient survey in immune thrombocytopenia (ITP): Identifying unmet needs related to treatment and disease control in patients living in the United States
Summary: Immune thrombocytopenia (ITP) is a chronic disease with primary therapeutic goals of platelet count recovery to safe levels to minimize active/future bleeding, alongside easing additional symptoms negatively impacting overall patient well‐being with consequent improvement in physical fatigue/energy levels, daily/work‐related activities and social/emotional health. Documentation of this rare disease is important for evaluating real‐world experiences in treatment satisfaction, expectations and unmet needs in disease management. This cross‐sectional, real‐world evidence survey was conducted from 9 February 2023 to 4 April 2023, by the Platelet Disorder Support Association and Sanofi in US adults diagnosed with ITP for ≥1 year. Results showed that although most patients receive and adhere to treatment, lack of sustained efficacy fuels a need for more effective therapy. Patients desired long‐term ITP control and were most concerned with increasing/stabilizing platelet counts and decreasing fatigue and bleeding severity. Better treatment was needed to ease burdensome health‐related quality of life symptoms, especially physical fatigue and anxiety, and decrease effects on daily life and activities. Additionally, involvement in shared decision‐making and engagement in educational, digital healthcare and psychological support were preferred. Overall, ITP patients desired long‐term disease management options that improved platelet counts, minimized bleeding and reduced physical fatigue and anxiety, while also engaging in patient support options.
- 17 August 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (3) , 1038-1046
Open AccessPatient survey in immune thrombocytopenia (ITP): Identifying unmet needs related to treatment and disease control in patients living in the United States
Summary: Immune thrombocytopenia (ITP) is a chronic disease with primary therapeutic goals of platelet count recovery to safe levels to minimize active/future bleeding, alongside easing additional symptoms negatively impacting overall patient well‐being with consequent improvement in physical fatigue/energy levels, daily/work‐related activities and social/emotional health. Documentation of this rare disease is important for evaluating real‐world experiences in treatment satisfaction, expectations and unmet needs in disease management. This cross‐sectional, real‐world evidence survey was conducted from 9 February 2023 to 4 April 2023, by the Platelet Disorder Support Association and Sanofi in US adults diagnosed with ITP for ≥1 year. Results showed that although most patients receive and adhere to treatment, lack of sustained efficacy fuels a need for more effective therapy. Patients desired long‐term ITP control and were most concerned with increasing/stabilizing platelet counts and decreasing fatigue and bleeding severity. Better treatment was needed to ease burdensome health‐related quality of life symptoms, especially physical fatigue and anxiety, and decrease effects on daily life and activities. Additionally, involvement in shared decision‐making and engagement in educational, digital healthcare and psychological support were preferred. Overall, ITP patients desired long‐term disease management options that improved platelet counts, minimized bleeding and reduced physical fatigue and anxiety, while also engaging in patient support options.